Expanded access program for MK-0518, an investigational HIV integrase inhibitor, established
21-Aug-2006 -
A worldwide expanded access program for HIV/AIDS patients with limited or no treatment options was announced by Merck & Co., Inc., Whitehouse Station, N.J., U.S.A., with respect to its investigational HIV integrase inhibitor, MK-0518, now in Phase III development. Program enrollment will begin in ...
AIDS
clinical trials
enzymes
+3